Clinical Trial Update: Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating stem cell transplantation after reduced-dose chemotherapy for sickle cell disease or thalassemia. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobin Sc Disease
• Sickle Cell Disease
• Thalassemia
• Thalassemia Major

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hemoglobinopathies, Anemia, Sickle Cell | Phase 2 | Status: TERMINATED